Ginkgo Bioworks Holdings (DNA) Current Deferred Revenue (2019 - 2026)

Ginkgo Bioworks Holdings (DNA) has 8 years of Current Deferred Revenue data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 55.69% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (down 55.69% YoY), and the FY2025 full-year result was $94.1 million, down 25.61% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $14.9 million, down from $94.1 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $222.6 million in Q4 2022 and bottomed at $14.9 million in Q1 2026.
• The 5-year median for Current Deferred Revenue is $42.8 million (2023), against an average of $86.3 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue jumped 368.98%; it then plunged 80.56% in 2024.
• A 5-year view of Current Deferred Revenue shows it stood at $222.6 million in 2022, then fell by 9.03% to $202.5 million in 2023, then sank by 37.53% to $126.5 million in 2024, then slipped by 25.61% to $94.1 million in 2025, then tumbled by 84.16% to $14.9 million in 2026.
• The last three Current Deferred Revenue figures came in at $14.9 million (Q1 2026), $94.1 million (Q4 2025), and $25.2 million (Q3 2025), per Business Quant data.

Peer Comparison